Dear All (and with thanks to Kevin Outterson for doing the heavy lifting on this note),
As you may recall, the US National Action Plan for Combatting Antimicrobial Resistant Bacteria (US NAP CARB) was launched in 2015 on the heels of the 2013 CDC report on antimicrobial threats (link to that report) and is/was a 5-year plan for the period 2015-2020. This report was the engine behind such US Government (USG) activities as PACCARB (the Presidential Advisory Council on CARB, link), CDC’s 2019 updated list of antibiotic resistance threats (link to that report), CARB-X (69 projects funded to date!), and much, much more.
Released today, we now have an updated US NAP for the period 2020-2025 (link)! There’s a whole lot in this report and we will summarize the top-level ideas:
- The 2020-25 NAP proposes the same 5 goals as the 2015-2020 plan:
- Goal 1: Slow the Emergence of Resistant Bacteria and Prevent the Spread of Resistant Infections
- Goal 2: Strengthen National One Health Surveillance Efforts to Combat Resistance
- Goal 3: Advance Development and Use of Rapid and Innovative Diagnostic Tests for Identification and Characterization of Resistant Bacteria
- Goal 4: Accelerate Basic and Applied Research and Development for New Antibiotics, Other Therapeutics, and Vaccines
- Goal 5: Improve International Collaboration and Capacities for Antibiotic-resistance
- The key frameshift for this report is that there is a serious effort to create integrated activities across the entire USG with very specific targets in the near term.
We can’t do a deep dive on everything, so here’s a selective tour of the topics of greatest direct impact for the R&D community.
Focusing in on Goal 3: (“Advance Development and Use of Rapid and Innovative Diagnostic Tests for Identification and Characterization of Resistant Bacteria”), we have these high-level objectives that span both bacterial and fungal pathogens:
- Develop new and enhance existing diagnostics for both pathogen identification and susceptibility in at least 10 funded projects by 2021 (p.29).
- Stimulate the appropriate adoption and use of diagnostics, supported by guidelines (p.30).
Focusing in on Goal 4: (“Accelerate Basic and Applied Research and Development for New Antibiotics, Other Therapeutics, and Vaccines”), we have these high-level objects that are focused on therapeutics for bacterial infections but that also include mentions of non-traditional approaches such as “bacteriophages, monoclonal antibodies, immune modulators, and phytochemicals” (p.31) as well as vaccines for both bacterial and fungal infections. Note also the integration of goals from both agriculture and DoD:
- Expand basic and applied interdisciplinary research with a target 1000 (!) publications by 2021.
- Welcome attention is paid to small steps to rebuild the research workforce, calling for at least 60 new or early-career investigators by 2021 (p.31).
- 100 new awards (including CARB-X, NIH, and BARDA awards) for pre-clinical therapeutic R&D by 2024 as well as additional candidate therapeutics from the DoD and the Department of Agriculture (p.33, Objective 2.1).
- In clinical development, 10 clinical therapeutic candidates by 2022, with 3 NDAs for antibacterial therapeutics by 2025 (p.33, Obj. 2.2).
- 25 preclinical programs for prevention by 2022, plus 2 for agricultural use (p.34). Along with this, there is a strong push to clarify pathways for preventatives, including vaccines (p. 34-35).
- FDA guidance in support of the above.
Within Goal 4, the sub-objectives of “promote sustainability of the commercial market for new antibiotic products” are of great interest and are quite specific, even if they fall short of calling for additional push and especially pull incentives (as the GAO noted earlier this year, link to report). The 4 initiatives are:
- Support the creation of a network of clinical trial sites to reduce barriers to research and to establish a comprehensive understanding of the safety and effectiveness of new antibiotic agents in challenging clinical settings and indications, to enroll patients by 2023 (p.35). (Note that this is a long-standing wish: See this prior manuscript in CID, this white paper sponsored by Wellcome Trust, and this concrete business plan developed by Wellcome Trust.)
- Examine changes in new technology add-on payments (NTAP) under the CMS Inpatient Prospective Payment System (IPPS) Final Rules, starting with the FY 2020 IPPS/long-term care hospital prospective payment system final rule, to inform potential additional actions. (But, note that HHS passed up the chance earlier this year to make a change that would have substantially moved the needle.)
- Strengthen commercial markets for antibiotic products through direct Public Health and National Security purchases by BARDA (p.36). This appears to call for more contracts similar to the one BARDA recently awarded to Paratek (link to press release).
- Support efforts to secure U.S.-based manufacturing infrastructure (p.36)
Within Goal 5 (” Improve International Collaboration and Capacities for Antibiotic-resistance”), global leadership:
- The most surprising commitment is to appoint a “US federal champion” to be the global ambassador on this issue (p.37): Can the US find its own Dame Sally?
- Goal 5 also featured strong support for global leadership and multilateral collaboration.
- Specific targets are included to assist 10-15 LMICs with national action plans (including WASH [Water, Sanitation, And Hygiene] capacity building) and 4 LMICs with capacity building for stewardship by 2022 (p.39).
- Also, there is a strong emphasis on building shared surveillance capacity: e.g., “one international AR Lab Network project” (p. 40).
- Plus, we are promised a global regulatory conference to align clinical trial regulations by 2023 (p.42). Kudos to the HHS Office of Global Affairs!
Wow! When combined with the momentum behind (i) the PASTEUR Act and its intent to create a delinked reward model (link to 30 Sep 2020 newsletter), (ii) the DISARM Act and its intent to level the playing field for use of novel inpatient antibiotics (background article by Kevin), and (iii) the CMS IPPS FY2020 Final Rule that begins to implement a way to recognize the overall cost of managing drug-resistant infections (link to 4 Aug 2019 newsletter), we are seeing a further increase in support of R&D for antibacterial agents.
Way to go on the part of our USG colleagues! How VERY exciting — the potential benefits to the global community are immense! Thank you!
So, please go get busy and discovery something new … and if you need inspiration, please check out the 28 April 2020 newsletter (link) entitled “Movies to Discovery Antibiotics By!” A few things have been added to the online version since the newsletter was sent around!
All best wishes, Kevin & John
Kevin Outterson, JD, Professor of Law, Boston University & Executive Director, CARB-X (these views are personal and do not necessarily reflect the views of CARB-X or any of its funders) @koutterson
John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.
Current funding opportunities (most current list is here):
- Novo REPAIR Impact Fund closed its most recent round on 31 Jul 2020. Go here for current details.
- 2020 funding rounds for CARB-X have not been announced.
- The Global AMR R&D Hub’s dynamic dashboard (link) summarizes funders and projects by geography, stage, and more.
- It’s not a funder, but AiCuris’ AiCubator offers incubator support to very early stage projects. Read more about it here.
- You might also be interested in the most current lists of R&D incentives (link) and priority pathogens (link)
Upcoming meetings of interest to the AMR community (most current list is here):
- In case you missed it, the 24 Sep 2020 Bootcamp #1 (“Moving from preclinical to clinical-stage: Challenges & opportunities”) is now available for replay: Get it here. The video for the 8 Oct 2020 Bootcamp #2 (“Exploring safety issues in antimicrobial drug development”) will follow shortly — check back at the current meetings webpage (link) to find it.
- 15 Oct 2020 (online, 9-10.30am EST) webinar chaired by Andrew Morris entitled “Prevention is Stronger than Cure”, the second webinar in a 4-part series sponsored by Wellcome Trust entitled “AMR in the Light of COVID-19 Webinar Series; From hypothetical to reality: How COVID-19 foretells a world without antibiotics.” Go here to register.
- 21 Oct 2020 (online, 9:00-10:30 CEST): GARDP-sponsored webinar entitled “Building better breakpoints: data and methods needed to determine breakpoints for new agents” moderated by Gunnar Kahlmeter. Go here to register.
- 21-25 Oct 2020 (online meeting): IDWeek 2020. Go here for details.
- 26-29 Oct 2020 (online meeting): Annual ESPID meeting (European Society for Pediatric ID, #38)
- 27 Oct 2020 (online, 9a-5p EST): FDA Workshop entitled “Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea.” Go here to register.
- 27 Oct 2020 (online meeting): BARDA Industry Day, a discussion of U.S. Government medical countermeasure priorities. Mark your calendar now and watch this website for details.
- [REGISTRATION LINK ADDED] 29 Oct 2020 (online, 4-6pm Paris): 5th anniversary ICARe (Interdisciplinary Course on Antibiotics and Resistance) webinar. This fabulous week-long residential course can’t be held this year but Patrice Courvalin is organizing a 2-h anniversary webinar both for former attendees and anybody else who is interested. Speakers will include Patrice as well as Helen Boucher, Gerry Wright, Erin Duffy, and me. Go here to register.
- 3-27 Nov 2020 (online, 4-week course, 10 sessions, 2-3h/session): First WHO Training Course in Infodemic Management. Infodemic = “information” + “epidemic” = rapid and far-reaching spread of both accurate and inaccurate information making it difficult to learn essential information about an issue. This is a training program for country-level preparedness. Application deadline is 18 Oct 2020. Go here for more.
- 5 Nov 2020 (online, 9-10.30am EST) webinar entitled “Aiming in the dark: what happens when disease spreads without diagnosis”, the third webinar in a 4-part series sponsored by Wellcome Trust entitled “AMR in the Light of COVID-19 Webinar Series; From hypothetical to reality: How COVID-19 foretells a world without antibiotics.” Go here to register.
- 17 Nov 2020 (online, 17:00-18:30 CET): GARDP-sponsored webinar entitled “Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)” moderated by Laura Piddock. Go here to register.
- 18-24 Nov 2020 (everywhere): World Antimicrobial Awareness Week. For resources, go here for WHO’s home page for the week. The focus will be on two messages: “Antimicrobials: handle with care” and “United to preserve antimicrobials.”
- 19 Nov 2020 (online, 9-10.30am EST) webinar chaired by Jeremy Knox entitled “Responding to difficult-to-treat infections: Role and responsibilities of governments, researchers, clinicians, industry and patients”, the final webinar in a 4-part series sponsored by Wellcome Trust entitled “AMR in the Light of COVID-19 Webinar Series; From hypothetical to reality: How COVID-19 foretells a world without antibiotics.” Go here to register.
- 9-12 Jul 2021 (Vienna): Annual ECCMID meeting (#31)
- 18-21 May 2021 (Albuquerque, New Mexico): Biannual meeting of the MSGERC (Mycoses Study Group Education and Research Consortium). Save-the-date announcement is here, details to follow.
- 20-24 June 2021 (Toronto): International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-12). Go here for details.
- 3-7 Jun 2021 (Anaheim), ASM Microbe 2021. Go here for details.
- 27 Jun-2 Jul 2021 (Ventura, CA): Gordon Research Conference entitled “Antimicrobial Peptides”. Go here for details, go here for the linked 26-27 Jun Gordon Research Seminar that precedes it.
- 5-21 Aug 2021 (Marine Biology Laboratory, Woods Hole, MA): Residential course entitled “Molecular Mycology: Current Approaches to Fungal Pathogenesis.” This 2-week intensive training program has run annually for many years and gets outstanding reviews. Go here for details.
- 8-11 Oct 2021 (Aberdeen, Scotland): 10th Trends in Medical Mycology. Go here for details.
- 16-24 Oct 2021 (Annecy, France): Interdisciplinary Course on Antibiotics and Resistance (ICARe). This is a soup-to-nuts residential course on antibiotics, antibiotic resistance, and antibiotic R&D. The course is very intense, very detailed, and gets rave reviews. Registration is here and is limited to 40 students.
- 6-11 Mar 2022 (Il Ciocco, Tuscany): Gordon Research Conference entitled “New Antibacterial Discovery and Development”. Go here for details, go here for the linked 5-6 Mar Gordon Research Seminar that precedes it.